Chargement en cours...
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib were the first two reversible inhibitors of the EGFR kinase. The discovery of EGFR kinase domain-activating mutations that s...
Enregistré dans:
| Publié dans: | Transl Lung Cancer Res |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AME Publishing Company
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6894987/ https://ncbi.nlm.nih.gov/pubmed/31857948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.04.20 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|